Muc1 cd227 fitc

Manufactured by BD

MUC1 (CD227)-FITC is a fluorescently labeled antibody that binds to the MUC1 antigen, also known as CD227. It is used in flow cytometry and other immunoassays to detect and quantify the presence of MUC1 on cell surfaces.

Automatically generated - may contain errors

Lab products found in correlation

Icam 1 cd54 pe, by BD (2 mentions) Cea cd66 fitc, by BD (2 mentions) Isotype matched controls, by BD (1 mentions) Facscalibur flow cytometer, by BD (1 mentions) Cellquest software, by BD (1 mentions) Cd24 percp cy5, by BD (1 mentions) Cd137l 4 1bbl pe, by BioLegend (1 mentions) Cd252 ox40l pe, by BioLegend (1 mentions) Pd l1 cd274 pe, by BioLegend (1 mentions) Ctla 4 cd152 pe, by BioLegend (1 mentions) Hla abc pe cy7, by BD (1 mentions) Live dead fixable violet dead stain kit, by Thermo Fisher Scientific (1 mentions) Facscalibur, by BD (1 mentions) Facsverse, by BD (1 mentions) Cd44 fitc, by BD (1 mentions)

2 protocols using muc1 cd227 fitc

Characterization of Tumor Cell Surface and Intracellular Antigens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell-surface and intracytoplasmic staining was performed as previously described [47 (link)]. Surface staining of tumor cells was performed using the primary labeled monoclonal antibodies HLA-A2-FITC, ICAM-1 (CD54)-PE, CEA (CD66)-FITC, MUC1 (CD227)-FITC, and the appropriate isotype-matched controls (BD Biosciences). For intracellular analysis of antigen processing machinery (APM) components, mouse IgG1 (MK2-23) isotype control, LMP2 (SY-1)-, LMP7 (HB2)-, TAP-1 (NOB1), calnexin (TO-5)-, β2-microglobulin (L368), and tapasin (TO-3)-specific monoclonal antibodies were developed and characterized as described [48 (link)-50 (link)]. Cellular fluorescence of 3×10⁴ cells was examined on a FACSCalibur flow cytometer using CellQuest software (BD Biosciences). Proteins were scored as markedly upregulated if confirmed statistically and if detection levels and/or mean fluorescence intensity (MFI) increased ≥ 25% following treatment and were not observed in control cells vs. isotype controls.

Gameiro S.R., Malamas A.S., Tsang K.Y., Ferrone S, & Hodge J.W. (2016). Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget, 7(7), 7390-7402.

+ Open protocol

+ Expand

Flow Cytometry Analysis of Irradiated Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

At 96 h post-irradiation, tumor cells were examined by flow cytometry, as previously described [13 (link)]. Cells were examined on FACSCalibur or FACSVerse cytometers, using the monoclonal antibodies targeting HLA-ABC-FITC, HLA-ABC-PE-Cy7, ICAM-1 (CD54)-PE, CEA (CD66)-FITC, MUC-1 (CD227)-FITC, CD24-PerCP-Cy5.5, CD44-FITC, and the appropriate isotype-matched controls (BD Biosciences, San Jose, CA). The monoclonal antibodies targeting CD70-FITC, CD275 (ICOSL)-PE, CD137L (4-1BBL)-PE, CD252 (OX40L)-PE, PD-L1 (CD274)-PE, CTLA-4 (CD152)-PE, and CD227 (MUC-1)-PE were obtained from BioLegend (San Diego, CA). Antibodies targeting CD133-APC (Miltenyi Biotec, San Diego, CA) and calreticulin-PE (R&D Systems, Minneapolis, MN) were also used. Isotype control staining was < 5% for all samples analyzed. Viability was examined using LIVE/DEAD Fixable Violet Dead Stain Kit (Thermo Fisher Scientific, Rockville, MD). Cell surface expression was evaluated on live cells gated by FSC/SSC and LIVE/DEAD staining.

Gameiro S.R., Malamas A.S., Bernstein M.B., Tsang K.Y., Vassantachart A., Sahoo N., Tailor R., Pidikiti R., Guha C.P., Hahn S.M., Krishnan S, & Hodge J.W. (2016). Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. International journal of radiation oncology, biology, physics, 95(1), 120-130.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!